Clinical Trial Update: Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer [Phase 1]

View source ↗

Summary

A phase 1 clinical trial is evaluating adaptive radiotherapy with Sacituzumab Govitecan for localized or muscle-invasive bladder cancer. The study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Shilpa Gupta, MD | Conditions: Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma | Phase 1 | Status: RECRUITING